All News HBM Holdings Limited

Equities

2142

KYG4403H1002

Market Closed - Hong Kong S.E. Other stock markets 04:08:05 2024-07-09 am EDT			5-day change	1st Jan Change
1.32 ^HKD	+1.54%		-5.04%	-31.96%

Jun. 27	Harbour BioMed Announces Resubmission of Biologics License Application for Batoclimab to NMPA for Treatment of Generalized Myasthenia Gravis	CI
May. 23	Hong Kong Shares Slip Further Down Amidst Interest Rate Reduction, Inflation Worries	MT

All News

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Harbour BioMed Announces Resubmission of Biologics License Application for Batoclimab to NMPA for Treatment of Generalized Myasthenia Gravis	Jun. 26	CI
Hong Kong Shares Slip Further Down Amidst Interest Rate Reduction, Inflation Worries	May. 23	MT
HBM Holdings Unit, AstraZeneca Sign License, Option Agreement for Targeted Cancer Treatment; Shares Rise 16%	May. 23	MT
Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies	May. 22	PR
Nona Biosciences Co., Ltd and AstraZeneca Enters into License and Option Agreement	May. 22	CI
HBM Holdings Returns to Profitability in 2023	Apr. 02	MT
Harbour BioMed Reports Full Year 2023 Financial Results	Mar. 28	PR
HBM Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
HBM Holdings Subsidiary Signs Antibody-Drug Conjugate Discovery Collaboration Deal	Feb. 27	MT
HBM Holdings Gets US FDA Clinical Trial Approval for Anti-Tumor Medication	Jan. 24	MT
Harbour BioMed Announces IND Clearance for HBM9027 in the U.S	Jan. 23	CI
HBM to Swing to 2023 Profit	Jan. 19	MT
Harbour BioMed Announces Positive Profit Alert	Jan. 18	PR
HBM Holdings Limited Provides Earnings Guidance for the Year Ended 31 December 2023	Jan. 18	CI
HBM Holdings Limited commences an Equity Buyback Plan for 76,842,891 shares, representing 10% of its issued share capital, under the authorization approved on June 8, 2023.	Dec. 19	CI
Harbour BioMed's Wholly-owned Subsidiary Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate	Dec. 15	AQ
HBM Holdings Unit Nona Biosciences Signs Licensing Deal with Seagen for Tumor Medication; Shares Fall 5%	Dec. 15	MT
HBM Holdings Limited Announces Results of the Phase Iii Clinical Trial, Which Demonstrated That the Efficacy in the Primary and Secondary Endpoints of Batoclimab	Dec. 01	CI
HBM Holdings Limited Announces Executive Changes	23-10-19	CI
HBM Swings to Profit in H1; Shares Up 6%	23-08-29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News HBM Holdings Limited

Equities

2142

KYG4403H1002

All News

Filters